Kian Azimpoor

Jun 12, 2024 | mondaq.com | Ross Margulies |Kian Azimpoor

Most health-care entities—including drug and device manufacturers, payers, and providers—have multiple touch points with federal regulation. The US Department of Health and Human Services (HHS) is both a direct regulator of the health-care products and services available to the public (such as through the Food and Drug Administration) and the nation's largest purchaser of health care (most notably through the Medicare program).

Jun 12, 2024 | healthaffairs.org | Sara Rosenbaum |MaryBeth Musumeci |Kian Azimpoor |Josemiguel Rodriguez

Section 1557 of the Affordable Care Act (codified as 42 U.S.C. §18116) is a civil rights landmark. At fewer than 300 words, Section 1557 (“1557”) is short in text. In this respect, it is similar to other health care civil rights laws on which it builds, such as Title VI of the 1964 Civil Rights Act, which prohibits discrimination by federally assisted entities based on race, national origin, sex, religion, or color.

May 27, 2024 | mondaq.com | Ross Margulies |Andrew Osborn LONDON |Patrick Brennan |Kian Azimpoor

In the latest legal development in the ongoing 340B contract pharmacy litigation, the United States Court of Appeals for the District of Columbia Circuit ruled earlier this week that the 340B Drug Pricing Program does not categorically prohibit manufacturers from imposing conditions on the distribution of covered drugs to covered entities, including to their contract pharmacies.

May 27, 2024 | mondaq.com | Ross Margulies |Andrew Osborn LONDON |Patrick Brennan |Kian Azimpoor

In the latest legal development in the ongoing 340B contract pharmacy litigation, the United States Court of Appeals for the District of Columbia Circuit ruled earlier this week that the 340B Drug Pricing Program does not categorically prohibit manufacturers from imposing conditions on the distribution of covered drugs to covered entities, including to their contract pharmacies.